The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Efficacy of High-Dose Glycine in the Treatment of Enduring Negative Symptoms of Schizophrenia
Abstract
BACKGROUND: Disturbances of N-methyl-D-aspartate (NMDA) receptor-mediated glutamatergic neurotransmission may play an important role in the pathophysiology of negative symptoms of schizophrenia. Glycine, a small nonessential amino acid, functions as an obligatory coagonist at NMDA receptors through its action at a strychnine-insensitive binding site on the NMDA receptor complex. Glycine-induced augmentation of NMDA receptor-mediated neurotransmission may thus offer a potentially safe and feasible approach for ameliorating persistent negative symptoms of schizophrenia. METHODS: Twenty-two treatment-resistant schizophrenic patients participated in a double-blind, placebo-controlled, 6-week, crossover treatment trial with 0.8 g/kg per day of glycine added to their ongoing antipsychotic medication. Clinical assessments, including the Brief Psychiatric Rating Scale (BPRS), the Positive and Negative Syndrome Scale (PANSS), the Simpson-Angus Scale for Extrapyramidal Symptoms, and the Abnormal Involuntary Movement Scale, were performed biweekly throughout the study. Clinical laboratory values and amino acid serum levels were monitored. RESULTS: Glycine treatment was well tolerated and induced increased glycine (P=.001) and serine (P=.001) serum levels. Glycine administration resulted in (1) a significant (P<.001) 30%+/-16% reduction in negative symptoms, as measured by the PANSS, and (2) a significant (P<.001) 30%+/-18% improvement in the BPRS total scores. The improvement in negative symptoms was unrelated to alterations in extrapyramidal effects or symptoms of depression. Low pretreatment glycine serum levels significantly predicted (r= 0.80) clinical response. CONCLUSION: These findings support hypoglutamatergic hypotheses of schizophrenia and suggest a novel approach for the pharmacotherapy of negative symptoms associated with this illness.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Brief Psychiatric Rating Scale.
Overall, J. E., & Gorham, D. R. (1962) · Psychological Reports · doi:10.2466/pr0.1962.10.3.799 · Cited by 11,090
(1976) · Medical Entomology and Zoology · Cited by 8,899
(1978) · Biochemical Education · doi:10.1016/0307-4412(78)90049-3 · Cited by 5,046
Krystal, J. H. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950030035004 · Cited by 3,330
A RATING SCALE FOR EXTRAPYRAMIDAL SIDE EFFECTS
SIMPSON, G. M., B., M., B., G., ANGUS, J. W. S., P., F. R. C., & M., D. P. (1970) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1970.tb02066.x · Cited by 3,264
Glycine potentiates the NMDA response in cultured mouse brain neurons
Johnson, J. W., & Ascher, P. (1987) · Nature · doi:10.1038/325529a0 · Cited by 3,139
Recent advances in the phencyclidine model of schizophrenia
(1991) · American Journal of Psychiatry · doi:10.1176/ajp.148.10.1301 · Cited by 2,904
Self-citationGlutamate receptor dysfunction and schizophrenia
Olney, J. W. (1995) · Archives of General Psychiatry · doi:10.1001/archpsyc.1995.03950240016004 · Cited by 1,685
Requirement for Glycine in Activation of NMDA-Receptors Expressed in Xenopus Oocytes
Kleckner, N. W., & Dingledine, R. (1988) · Science · doi:10.1126/science.2841759 · Cited by 1,422
Deficit and nondeficit forms of schizophrenia: the concept
(1988) · American Journal of Psychiatry · doi:10.1176/ajp.145.5.578 · Cited by 1,332
Cited by
Moghaddam, B., & Javitt, D. (2012) · Neuropsychopharmacology · doi:10.1038/npp.2011.181 · Cited by 1,035
Self-citationMiyamoto, S., Duncan, G. E., Marx, C. E., & Lieberman, J. A. (2005) · Molecular Psychiatry · doi:10.1038/sj.mp.4001556 · Cited by 988
Glutamate and Schizophrenia: Beyond the Dopamine Hypothesis
Coyle, J. T. (2006) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-006-9062-8 · Cited by 917
“The findings with the full agonist glycine have been replicated in two additional clinical trials (Heresco-Levy et al., 1999; Javitt et al., 2001).”
ResultThe Emerging Role of Glutamate in the Pathophysiology and Treatment of Schizophrenia
Goff, D. C., & Coyle, J. T. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.9.1367 · Cited by 915
D-Alanine Added to Antipsychotics for the Treatment of Schizophrenia
Tsai, G. E., Yang, P., Chang, Y.-C., & Chong, M.-Y. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.06.032 · Cited by 674
Increased cortical kynurenate content in schizophrenia
Schwarcz, R., Rassoulpour, A., Wu, H.-Q., Medoff, D., Tamminga, C. A., & Roberts, R. C. (2001) · Biological Psychiatry · doi:10.1016/s0006-3223(01)01078-2 · Cited by 590
Glutamatergic mechanisms in schizophrenia
Tsai, G., & Coyle, J. T. (2002) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.42.082701.160735 · Cited by 577
Javitt, D. C. (2007) · International Review of Neurobiology · doi:10.1016/s0074-7742(06)78003-5 · Cited by 560
Self-citationKrystal, J. H., D'Souza, D. C., Mathalon, D., Perry, E., Belger, A., & Hoffman, R. (2003) · Psychopharmacology · doi:10.1007/s00213-003-1582-z · Cited by 530
Glutamate as a therapeutic target in psychiatric disorders
Javitt, D. C. (2004) · Molecular Psychiatry · doi:10.1038/sj.mp.4001551 · Cited by 524
Self-citationConvergence of biological and psychological perspectives on cognitive coordination in schizophrenia
Phillips, W. A., & Silverstein, S. M. (2003) · Behavioral and Brain Sciences · doi:10.1017/s0140525x03000025 · Cited by 445
“Second, in patients whose glycine levels are initially sub-optimal, glycine agonists (which then facilitate NMDA-channel opening) can improve negative symptoms (Goff et al. 1999; Heresco-Levy et al. 1999).”
BackgroundPersistent Negative Symptoms in Schizophrenia: An Overview
Buchanan, R. W. (2007) · Schizophrenia Bulletin · doi:10.1093/schbul/sbl057 · Cited by 443
Converging Evidence of NMDA Receptor Hypofunction in the Pathophysiology of Schizophrenia
COYLE, J. T., TSAI, G., & GOFF, D. (2003) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1300.020 · Cited by 442
Buchanan, R. W. (2005) · Schizophrenia Bulletin · doi:10.1093/schbul/sbi020 · Cited by 438
Glutamate, Dopamine, and Schizophrenia: From Pathophysiology to Treatment
LARUELLE, M., KEGELES, L. S., & ABI‐DARGHAM, A. (2003) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1300.063 · Cited by 437
Buchanan, R. W., Javitt, D. C., Marder, S. R., Schooler, N. R., Gold, J. M., McMahon, R. P., Heresco-Levy, U., & Carpenter, W. T. (2007) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2007.06081358 · Cited by 419
Self-citationWeiner, I. (2003) · Psychopharmacology · doi:10.1007/s00213-002-1313-x · Cited by 391
Heresco-Levy, U., Javitt, D. C., Ebstein, R., Vass, A., Lichtenberg, P., Bar, G., Catinari, S., & Ermilov, M. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2004.12.037 · Cited by 386
Self-citationGlutamate hypothesis in schizophrenia
Uno, Y., & Coyle, J. T. (2019) · Psychiatry and Clinical Neurosciences · doi:10.1111/pcn.12823 · Cited by 367
Early-stage visual processing and cortical amplification deficits in schizophrenia
Butler, P. D., Zemon, V., Schechter, I., Saperstein, A. M., Hoptman, M. J., Lim, K. O., Revheim, N., Silipo, G., & Javitt, D. C. (2005) · Archives of General Psychiatry · doi:10.1001/archpsyc.62.5.495 · Cited by 362
Self-citationTsai, G., Lane, H.-Y., Yang, P., Chong, M.-Y., & Lange, N. (2004) · Biological Psychiatry · doi:10.1016/j.biopsych.2003.09.012 · Cited by 342
Molecular aspects of glutamate dysregulation: implications for schizophrenia and its treatment
Konradi, C., & Heckers, S. (2003) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(02)00328-5 · Cited by 336
Javitt, D. C., Zukin, S. R., Heresco-Levy, U., & Umbricht, D. (2012) · Schizophrenia Bulletin · doi:10.1093/schbul/sbs069 · Cited by 322
Self-citationThe genetic aetiology of childhood depression: a review
Rice, F., Harold, G., & Thapar, A. (2002) · Journal of Child Psychology and Psychiatry · doi:10.1111/1469-7610.00004 · Cited by 313
l-Serine in disease and development
de KONING, T. J., SNELL, K., DURAN, M., BERGER, R., POLL-THE, B.-T., & SURTEES, R. (2003) · Biochemical Journal · doi:10.1042/bj20021785 · Cited by 295
Rom, O., Liu, Y., Liu, Z., Zhao, Y., Wu, J., Ghrayeb, A., Villacorta, L., Fan, Y., Chang, L., Wang, L., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aaz2841 · Cited by 280
Lane, H.-Y., Chang, Y.-C., Liu, Y.-C., Chiu, C.-C., & Tsai, G. E. (2005) · Archives of General Psychiatry · doi:10.1001/archpsyc.62.11.1196 · Cited by 271
Fergusson, D. (2004) · BMJ · doi:10.1136/bmj.37952.631667.ee · Cited by 264
High-dose glycine added to olanzapine and risperidone for the treatment of schizophrenia
Heresco-Levy, U., Ermilov, M., Lichtenberg, P., Bar, G., & Javitt, D. C. (2004) · Biological Psychiatry · doi:10.1016/s0006-3223(03)00707-8 · Cited by 222
Self-citationMarx, C. E., Keefe, R. S. E., Buchanan, R. W., Hamer, R. M., Kilts, J. D., Bradford, D. W., Strauss, J. L., Naylor, J. C., Payne, V. M., Lieberman, J. A., et al. (2009) · Neuropsychopharmacology · doi:10.1038/npp.2009.26 · Cited by 193
Abi-Dargham, A., & Laruelle, M. (2005) · European Psychiatry · doi:10.1016/j.eurpsy.2004.11.003 · Cited by 179
GOFF, D., CATHER, C., GOTTLIEB, J., EVINS, A., WALSH, J., RAEKE, L., OTTO, M., SCHOENFELD, D., & GREEN, M. (2008) · Schizophrenia Research · doi:10.1016/j.schres.2008.08.012 · Cited by 144
“Previous trials in which glycine site agonists demonstrated efficacy for negative symptoms clearly displayed a gradual improvement in symptom ratings over time with a plateau after approximately 6 weeks (Goff et al., 1999b; Heresco-Levy et al., 1999; Tsai et al., 1998).”
Apathy in schizophrenia: clinical correlates and association with functional outcome
Kiang, M., Christensen, B. K., Remington, G., & Kapur, S. (2003) · Schizophrenia Research · doi:10.1016/s0920-9964(02)00433-4 · Cited by 118
de Bartolomeis, A., Barone, A., Vellucci, L., Mazza, B., Austin, M. C., Iasevoli, F., & Ciccarelli, M. (2022) · Molecular Neurobiology · doi:10.1007/s12035-022-02976-3 · Cited by 113
Glycine transport inhibitors in the treatment of schizophrenia
Javitt, D. C. (2012) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-25758-2_12 · Cited by 83
Self-citationAdjunctive glycine in the treatment of obsessive-compulsive disorder in adults
Greenberg, W. M., Benedict, M. M., Doerfer, J., Perrin, M., Panek, L., Cleveland, W. L., & Javitt, D. C. (2009) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2008.10.007 · Cited by 80
Self-citationEgerton, A., Fusar-Poli, P., & M. Stone, J. (2012) · Current Pharmaceutical Design · doi:10.2174/138161212799316244 · Cited by 36
Metadata
- Authors
- Heresco-Levy, U., Javitt, D. C., Ermilov, M., Mordel, C., Silipo, G., & Lichtenstein, M.
- Venue
- Archives of General Psychiatry
- Publisher
- American Medical Association (AMA)
- Published
- 1999-01-01
- Volume
- 56
- Issue
- 1
- Pages
- 29
- ISSN
- 0003-990X (ISSN-L)
- OpenAlex
- W2022180773
- Cited by
- 487
- References
- 35
- FWCI
- 13.80
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.